Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).



Kurztitel: Kura KO-TIP 007

Untersuchte Krankheit: hnscc

Studienleitung: PD Dr. med. Konrad Klinghammer
Klinik, Institut: Charité Comprehensive Cancer Center

Patient/-in (krank)
Stand: 31.10.2020

Zurück zur Übersicht



Sie befinden sich hier:

Seiteninhalt

Studienbeschreibung

Titel

Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

Kurztitel

Kura KO-TIP 007

EudraCT-Nr.

2018-001437-40

Wissenschaftliche Kurzbeschreibung

A Pivotal Study of Tipifarnib in Patients with Recurrent or Metastatic Head and Neck Squamous Cell
Carcinoma (HNSCC) with HRAS mutations who have Failed At least One Prior Line of Therapy

Untersuchte Krankheit, Gesundheitsproblem

ICD-Code
  • C10.0 - Vallecula epiglottica

Charakteristika

Studientyp

Interventionell

Studienphase

II

Zurück zur Übersicht